TB-7428 · REV B · Technical newsheet

Lab InstrumentationDevice profile

Araceli adds investor as $4.5 million round funds expansion

Araceli closed a $4.5 million round, added Jeff Swickard and plans a 2027 consumables rollout. Its sixfold 2026 revenue forecast and top-20 pharma use remain company claims.

By Sophie Lindqvist4 min read848 words

Features

  • $4.5 million financing round closed; Jeff Swickard added as an investor.
  • Broader rollout of consumable products planned for 2027.
  • 2026 revenue expected at about six times the level from two years earlier.
  • Founded in 2020 and spun out of Phoseon Technology in 2023.
  • About 30 employees; company claims use by 10 of the 20 largest pharmaceutical companies.
Araceli Biosciences Adds Jeff Swickard as Investor in $4.5 Million Financing Round
Device photoAraceli Biosciences Adds Jeff Swickard as Investor in $4.5 Million Financing Round — Hans / pixabay

By Sophie Lindqvist

A $4.5 million financing round closed at Tigard, Oregon-based Araceli Biosciences, which added Jeff Swickard as an investor and prepares to expand its cellular-imaging products. Swickard’s investment amount, the round’s valuation, the resulting ownership interests and the other participants were not disclosed.

Araceli expects its 2026 revenue to reach approximately six times its level from two years earlier after a period of commercial expansion. The company supplied neither historical revenue figures nor a forecast method, so the projection remains a company estimate rather than a reported result.

What does the financing fund?

The proceeds support continued commercialization of the Endeavor cellular imaging platform and development of consumable products, meaning items laboratories use and replenish during routine work, for a growing customer base. Araceli plans a broader rollout of those products in 2027, but the announcement specifies no composition, pack size, shelf life, unit price or total cost.

Araceli calls this its second phase of commercialization, shifting beyond installed imaging systems to introduce consumable products optimized for existing customers. The stated goal is broader use in pharmaceutical research laboratories. Takeaway: Labs may gain a fuller workflow in 2027, but procurement details remain missing.

How does the platform fit drug development?

Founded in 2020 and spun out of Phoseon Technology in 2023, Araceli develops what it calls high-performance imaging systems and artificial-intelligence-driven analysis software. Pharmaceutical and biotechnology researchers use the tools to monitor cellular responses to experimental drug compounds, collect biological data and analyze it earlier in drug development.

Araceli says 10 of the world’s 20 largest pharmaceutical companies use its systems. Its customers operate across North America and Europe, with a presence in the San Francisco Bay Area, Boston, London and Berlin.

The announcement reports market reach but no instrument-performance evidence. It omits:

  • image resolution, meaning the smallest recorded detail, and magnification;
  • signal sensitivity and acquisition rate;
  • calibration interval, meaning time between formal performance checks, and software-validation procedures; and
  • reproducibility benchmarks and comparisons with competing cellular-imaging methods.

Takeaway: The claimed top-20-company reach indicates commercial traction, while instrument-level evidence remains unavailable.

What changes with human-cell assays?

Endeavor supports New Approach Methodologies, or NAMs, which use human cell-based assays to evaluate a compound’s potential safety and effectiveness while reducing reliance on traditional animal testing. In the workflow Araceli describes, imaging supplies cellular-response data for that evaluation earlier in drug development.

The company presents this combination as helping laboratories collect and analyze biological data earlier. It discloses no assay protocols, reference ranges, acceptance criteria or evidence that its imaging output meets regulatory expectations.

Human-cell assays replace part of the evaluation traditionally handled through animal testing, so an imaging endpoint becomes part of an assay-based safety and effectiveness assessment. Image quality alone cannot establish equivalence to an animal model or predict clinical performance, and the buying decision requires compound- and assay-specific validation against the laboratory’s intended comparison method. Takeaway: NAM support may reduce animal use, but laboratories need validation evidence before treating the platform as a substitute.

What did the investors say?

Araceli Biosciences chief financial officer Shawn MacDonald said: “We’re especially grateful to Jeff Swickard for his investment and for his commitment to making science more humane. His support reflects a belief that we share, which is that better science and more humane science go hand-in-hand.” The statement connects capital to the company’s stated mission rather than a released instrument specification.

Swickard said: “We are excited to join an impressive group of investors in Araceli Biosciences, an innovative Oregon company developing technology with the potential to modernize scientific research and reduce the need for animal testing.” He described the investment as support for Oregon’s technology and life sciences industry, particularly companies developing alternatives to animal-based research.

Neither quotation supplies a performance metric, financial term or product-launch date beyond the separately stated 2027 consumables plan. The announcement does not identify Swickard’s role beyond investor or describe any board, operating or commercial commitment. Takeaway: The investor case rests on research-humannity and commercialization goals, not disclosed technical benchmarks or deal economics.

How large is the company?

Araceli employs approximately 30 people, most of whom work at its Tigard headquarters. The company did not identify the round’s other participants or disclose additional financial terms.

The announcement also does not split the $4.5 million among platform commercialization, consumable development, hiring or other uses. That leaves buyers and prospective investors without a way to compare product investment with near-term operating requirements. Takeaway: Headcount and financing size are visible, but capital allocation and unit-level revenue and cost data are not.

For laboratory directors, the adoption test is concrete: will documented platform performance, validated assays and costed 2027 consumables justify expansion within existing workflows? For investors, the parallel test is whether the approximately sixfold 2026 revenue projection becomes disclosed revenue, and whether valuation and ownership details emerge. Until then, the announcement documents a planned expansion, not independent performance or financial verification.

via citybiz.co (Source)

Filed under

  • cellular-imaging
  • laboratory-instruments
  • pharmaceutical-research
  • new-approach-methodologies
  • animal-testing-alternatives
Share this article:

More from Sophie Lindqvist

Sophie Lindqvist

Show full bio

News editor covering regulation, policy and their impact on Instruments, test and measurement at Testbench Report.

110 articles

Application notes

« Previous articleNext article »